Data presented from clinical and preclinical studies Melanocortin agonism reduces stress signaling and resolves inflammation Potential to treat inflammatory diseases without immunosuppression CRANBURY, N.J., Oct. 24, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a...
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
Seaking AlphaSeeking Alpha / Seaking Alpha 12 hours ago 1 Views
Comments